WuXi XDC Licenses Cancer Tech to AI Biotech Firm Earendil in Deal Potentially Valued at $885 Million
By Jason Chau
Chinese pharmaceutical company WuXi XDC is partnering with U.S. biotech startup Earendil Labs in a deal it says could be worth up to $885 million.
Under the agreement, Hong Kong-listed WuXi will grant Earendil, which uses artificial-intelligence for drug discovery, exclusive global license to its proprietary cancer therapy technology.
Earendil will use the technology to conjugate antibodies discovered through its AI intelligence platform to develop candidates for cancer treatment, WuXi said in a statement Friday.
Including upfront and milestone payments, WuXi said the deal could have a potential value of about $885 million. It will also be eligible to receive tiered royalties on sales of any products.
WuXi will support the chemical, manufacturing and controls stage of drug development, while Earendil will focus on commercialization.
Earendil specializes in using machine learning to research and produce innovative drugs targeting conditions including autoimmune diseases.
Write to Jason Chau at jason.chau@wsj.com
(END) Dow Jones Newswires
February 27, 2026 05:59 ET (10:59 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Why This Vanguard ETF Is One of the Best
The Best AI Stocks to Buy Now
United States